ClinicalTrials.gg
CompletedNCT01929863Updated Aug 16, 2017Results posted

Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 in Type 2 Diabetes Patients Taking Metformin

A Phase 2 interventional study of GSK2330672 and Placebo in Diabetes Mellitus, Type 2, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to participants aged 30 Years to 64 Years. Per ClinicalTrials.gov, last updated 2017-08-16.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
30 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 136 studies in Diabetes Mellitus, Type 2 by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Diabetes Mellitus, Type 2 · GlaxoSmithKline.

Enrollment
109th of 125
16 · median 70
Started
2013
with 3 others
Phase 2
22 of 136
none open now
Registered
124th of 136
by date

Among the 136 studies in Diabetes Mellitus, Type 2 by GlaxoSmithKline, this one is the 109th largest by enrollment of the 125 interventional ones that give a count, is one of 4 that started in 2013, is one of 22 in phase 2, and was the 124th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 136 studies in Diabetes Mellitus, Type 2 by GlaxoSmithKline is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 30 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 136 studies in Diabetes Mellitus, Type 2 by GlaxoSmithKline as a file.
02

Study summary

Metformin may have complex interactions in the gut and is generally first line therapy for type 2 diabetes mellitus (T2DM). It is important to understand whether there are significant pharmacokinetic or pharmacodynamic interactions when GSK2330672 is co-administered with metformin in subjects with T2DM. The purpose of this study is to investigate the safety and tolerability of GSK2330672 administered for 7 days to subjects with T2DM taking metformin. This will be a two-period crossover study; subjects will receive either GSK2330672 or placebo for 7 days in each period separated by a washout period of 13 to 15 days. All subjects will receive metformin throughout the study

03

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • Metformin
  • Diabetes
04

Who can participate

Ages eligible
30 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females aged between 30 and 64 years of age inclusive, at the time of signing the .
  • Subjects with documented T2DM diagnosis (diagnosed not less than 3 months prior to screening); AND one of the following: taking stable metformin 850 milligrams (mg) twice daily (BID) (or the equivalent of 1700 mg/day) for at least 4 weeks prior to screening and a glycosolated (HbA1c) of >=7.0% to \<=11% at screening; OR taking stable metformin of >=1000 mg/day to \<1700 mg/day for at least 4 weeks prior to screening and a HbA1c of >=7.5% to \<=11% at Screening; OR taking stable metformin of >1700 to \<=2000 mg/day for at least 4 weeks prior to screening and a HbA1c of >=7.0% to \<=10% at screening; not taking other anti-diabetic medications.
  • All T2DM subjects must meet label recommendations for metformin, including: Adequate renal function, as evidenced by the Modification of Diet in Renal Disease estimate of >=60 milliliters (mL)/minute (min); No conditions which make hypoxia, dehydration, or sepsis likely; No clinical or laboratory evidence of hepatic disease (including history of cholecystitis or symptomatic gallstones) and cardiac disease (including a history of myocardial infarction or heart failure). Subjects with a history of cholelithiasis and uncomplicated cholecystectomy more than 3 months before screening may be eligible if approved by the GlaxoSmithKline (GSK) Medical Monitor; No excessive alcohol intake.
  • C-peptide of >0.8 nanogram (ng)/mL at screening visit.
  • Urine albumin-to-creatinine ratio \<30 mg/gram (g).
  • Fasting plasma glucose \<280 mg/decilitre (dL)
  • (BMI) of 24 to 40 kilograms (kg)/square meter (m\^2), inclusive
  • In good general health with (in the opinion of the investigator) no and relevant abnormalities of medical history or physical examination that would introduce additional risk factors or interfere with study procedures or objectives, based on a medical evaluation including medical history, physical examination, vital signs and laboratory tests.
  • Female subjects of non-. Non-childbearing potential is defined as: Pre-menopausal females with a documented tubal ligation or hysterectomy [for this definition, "documented" refers to the outcome of the investigator's/designee's review of the subject's medical history for study eligibility, as obtained via a verbal interview with the subject or from the subject's medical records]. defined as 12 months of spontaneous amenorrhea. In questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 milli international units (MIU)/mL and estradiol \< 40 picograms (pg)/mL (\<147 picomole [pmol]/liter [L]) is confirmatory. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the acceptable methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment. For most forms of HRT, at least 2 to 4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method.
  • Male subjects with female partners of child-bearing potential must agree to use one of the acceptable contraception methods. This criterion must be followed from the time of the first dose of study medication until follow up visit.
  • Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form

Exclusion criteria

Exclusion Criteria:

  • CRITERIA BASED UPON MEDICAL HISTORIES:
  • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome).
  • History of chronic or acute pancreatitis. Approval from the GSK Medical Monitor must be obtained for subjects with a past history of pancreatitis more than 12 months from the start of the treatment period (subjects with a history of pancreatitis within 12 months prior to the start of the treatment period are excluded).
  • History of gastrointestinal (GI) disease (e.g., irritable bowel disease, chronic or current diarrhea, inflamed bowel, steatorrhoea/fat malabsorption, celiac disease, symptomatic lactose intolerance). Subjects with gastroparesis requiring treatment are excluded.
  • History of significant cardiovascular disease including acute myocardial infarction, stroke, hospitalization for acute coronary syndrome, heart failure within the previous 12 months.
  • Uncontrolled hypertension, as evidenced by systolic pressure >160 or diastolic pressure >90. Subjects taking anti-hypertensive medications are permitted.
  • Significant abnormalities, defined as follows: Heart rate (resting) \<50 and >100 beats per minute (bpm); PR Interval \<120 and >220 milliseconds (msec); QRS duration \<70 and >120 msec
  • History of untreated pernicious anemia or who have laboratory parameters suggestive of subclinical megaloblastic anemia (e.g., increased mean corpuscular volume with low red blood cells count and/or level).
  • Current or relevant previous significant medical disorder that may require treatment or make the subject unlikely to fully complete the study, or any condition that, in the opinion of the investigator, presents undue risk from the study medication or procedures.
  • Thyroid Disease: Uncorrected Thyroid Dysfunction: Fasting plasma thyroid stimulating hormone (TSH) outside of the normal range, as determined at the screening visit; Subjects on stable thyroid replacement therapy and with TSH in the normal range are eligible if approved by the GSK Medical Monitor; Unevaluated thyroid nodule or goiter at Screening.
  • History of regular alcohol consumption within 6 months of the study defined as: An average weekly intake of >14 drinks for males or >7 drinks for females. One drink is equivalent to 12 g of alcohol: 12 ounces (360 mL) of beer, 5 ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled spirits.
  • History of sensitivity to heparin or heparin-induced thrombocytopenia.
  • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation
  • CRITERIA BASED UPON DIAGNOSTIC ASSESSMENTS:
  • , alkaline phosphatase and > 1.5x (ULN) (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).
  • Based on averaged values of triplicate ECGs obtained at least 1 minute apart within approximately 15 minutes: QTcF >=450 msec; or QTcF >=480 msec in subjects with Bundle Branch Block (subjects with left bundle branch block are excluded)
  • A positive pre-study surface antigen or positive antibody result within 3 months of screening
  • A positive test for antibody
  • A positive pre-study drug/alcohol urine screen
  • A subject with a positive urine cotinine test result will be excluded from the study unless in the judgment of the Investigator the subject will be able to abstain from using tobacco for the duration of the in-house periods of the study.
  • OTHER CRITERIA
  • Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
  • The subject has participated in a clinical trial and has received an product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
  • Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
  • A subject with a fasting plasma glucose at Day -1 that is more than 100 mg/dL lower than at screening must not be randomized, unless on a repeat test the value less than 100 mg/dL of the screening value.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Arm A

    Subjects will receive metformin 850 mg BID for 7 days, GSK2330672 45 mg BID on Days 1 and 2 and GSK2330672 90 mg BID on Days 3 to 7 in treatment period 1. Subjects will receive metformin 850 mg BID for 7 days, placebo (matching 45 mg GSK2330672) BID on Days 1 and 2 and placebo (matching 90 mg GSK2330672) BID on Days 3 to 7 in treatment period 2. Treatment periods will be separated by a washout period of 13 to 15 days in which subjects will continue metformin 850 mg BID only

    Drug: GSK2330672 · Drug: Placebo · Drug: Metformin

  • Experimental
    Arm B

    Subjects will receive metformin 850 mg BID for 7 days, placebo (matching 45 mg GSK2330672) BID on Days 1 and 2 and placebo (matching 90 mg GSK2330672) BID on Days 3 to 7 in treatment period 1. Subjects will receive metformin 850 mg BID for 7 days, GSK2330672 45 mg BID on Days 1 and 2 and GSK2330672 90 mg BID on Days 3 to 7 in treatment period 2. Treatment periods will be separated by a washout period of 13 to 15 days in which subjects will continue metformin 850 mg BID only

    Drug: GSK2330672 · Drug: Placebo · Drug: Metformin

Interventions

  • GSK2330672 will be supplied as oral solution, and will be administered BID \[45 mg (2 days repeat dose) and 90 mg (5 days repeat dose) in each period\]

  • DrugPlacebo

    GSK2330672 matching placebo will be supplied as oral solution, and will be administered BID (7 days of dosing in each period)

  • Metformin 850 mg will be administered BID from Run-in period till Day 7 of period 2

06

What researchers measure

Primary outcomes

  1. Number of Participants With at Least One Adverse Event (AE), Serious Adverse Event (SAE) or Death

    An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in this definition, associated with liver injury and impaired liver function defined as alanine aminotransferase (ALT) \>=3 x upper limit of normal (ULN), and total bilirubin \>=2 x ULN or international normalized ratio \>1.5.

    Time frame: Up to Follow-up (up to 53 days)

  2. Number of Participants With the Indicated Clinical Chemistry Values of Potential Clinical Importance (PCI) at Any Time Post Baseline

    The assessments were done at Day -1, Day 3, Day 8 and Follow-up under fasting condition. The following laboratory parameters of clinical chemistry were analyzed: blood urea nitrogen (BUN), creatinine, fasting triglycerides (TGs), total cholesterol, low-density lipoprotein cholesterol (LDLc), high-density lipoprotein cholesterol (HDLc), sodium, potassium, chloride, total bicarbonate, calcium, aspartate aminotransferase (AST), ALT, gamma glutamyltransferase (GGT), alkaline phosphatase, total and direct bilirubin, uric acid, albumin and total protein. Baseline was the assessment done on Day -1 (pre dose). Only those parameters for which at least one value of PCI was reported are summarized. Data is reported for participants with high glucose PCI, where the PCI value for T2DM participants was ( low \< 3.8857 millimole per liter (mmol/L); high \> 15 mmol/L; normal range was 3.61 - 5.5 mmol/L).

    Time frame: Up to Follow-up (up to 53 days)

  3. Number of Participants With the Indicated Haematology Values of PCI at Any Time Post Baseline

    The assessments were done at Day -1, Day 3, Day 8 and Follow-up under fasting condition. The following laboratory parameters of clinical haematology were analyzed: platelet count, red blood cells (RBC) count, absolute white blood cells (WBC) count, reticulocyte count, hemoglobin, hematocrit, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline was the assessment done on Day -1 (pre dose). Only those parameters for which at least one value of PCI was reported are summarized. Data is reported for participants with high WBC counts PCI, where the PCI value for T2DM participants was (relative low : 0.5 multiplier of lower limit of normal \[LLN\]; relative high : 1.82 multiplier of upper limit of normal \[LLN\]; where normal range was 3.8 - 10.8 giga cells per liter (GI/L).

    Time frame: Up to Follow-up (up to 53 days)

  4. Number of Participants With Abnormal Values of Urine Microscopic Analysis of Bacteria, Hyaline Casts (Semi-quantitive), RBC, Squamous Epithelial Cells and WBC at Any Time Post Baseline

    The assessments were done at Day -1, Day 3, Day 8 and Follow-up under fasting condition for microscopic analysis of bacteria, hyaline casts (semi-quantitive), RBC, squamous epithelial cells and WBC. Baseline was the assessment done on Day -1 (pre dose). The participants were categorized as 0-5, 6-10, 10-20, moderate, few and many. Only those parameters for which at least one value of these categories reported are summarized.

    Time frame: Up to Follow-up (up to 53 days)

  5. Number of Participants With Abnormal Values of Urine Dipstic Analysis of Occult Blood, Glucose, Ketones and Proteins at Any Visit Post Baseline

    The assessments were done at Day -1, Day 3, Day 8 and Follow-up under fasting condition for urine dipstic analysis of occult blood, glucose, ketones and proteins. Baseline was the assessment done on Day -1 (pre dose). The participants were categorized with results of 1+, 2+, 3+ and trace. Only those parameters for which at least one value of these categories reported are summarized.

    Time frame: Up to Follow-up (up to 53 days)

  6. Mean Specific Gravity of Urine at Any Visit Post Baseline

    Urine specific gravity is a laboratory test that shows the concentration of all chemical particles in the urine. The assessments were done at Day -1, Day 3, Day 8 and Follow-up under fasting condition. Baseline was the assessment done on Day -1 (pre dose).

    Time frame: Up to Follow-up (up to 53 days)

  7. Number of Participants With Abnormal Results for Fecal Occult Blood Test

    The assessment of fecal occult blood was done on Day 8. Stool sample was obtained any time after dosing on Day 7.

    Time frame: Day 8 of both treatment periods

  8. Number of Participants With Vital Sign Values of PCI at Any Time Post Baseline

    Vital signs assessment included heart rate (HR), systolic blood pressure (SBP) and diastolic blood pressure (DBP). Assessments were completed at pre morning dose on Day 1 (Baseline), Day 3, Day 8 (before discharge) and Follow-up. Criteria for vital sign values meeting PCI for Type 2 diabetes mellitus (T2DM) included: SBP \<85 and \>160 millimeters of mercury (mmHg), DBP \<45 and \>100 mmHg and HR \<40 and \>110 beats per minute (bpm). Only those parameters for which at least one value of PCI was reported are summarized.

    Time frame: Up to Follow-up (up to 53 days)

  9. Number of Participants With Abnormal (Clinically Significant or Not Clinically Significant) Findings in 12-lead Electrocardiogram (ECG) at Any Time Post Baseline

    12-lead ECG assessments were obtained pre-dose at Day 1, Day 3, Day 8 (before discharge) and Follow-up. The assessments were done using an ECG machine that automatically calculated the heart rate and measures PQ, QRS, QT, and QTc(B) intervals. Abnormal ECG findings (clinically significant or not clinically significant) were categorized. The abnormal PCI range for T2DM participants include QTc interval of \>450 to \<=480 milliseconds (msec) and increase from Baseline QTc interval of \> 30 to \<=60 msec, PR interval \<110 and \>220 msec and QRS interval \<75 and \>110 msec. ECG abnormalities were categorized as clinically significant or not clinically significant based on PCI criteria and judgment of the investigator. Baseline was defined as the mean of three replicate assessments at pre-dose on Day 1.

    Time frame: Up to Follow-up (up to 53 days)

  10. Number of Events of Stool or Bowel Movements of Participants Using Bristol Stool Form Rating (BSFR) Scale Across Day 1 to 7

    The BSFR Scale assessed stool quality using a 7-point scale, where 1=separate hard lumps like nuts (difficult to pass) and 7=watery, no solid pieces (entirely liquid). Bristol Stool Form Scale Rating: 1=separate hard lumps, like nuts, 2=sausage shaped but lumpy, 3=like a sausage or snake but with cracks on its surface, 4=like a sausage or snake, smooth and soft, 5=soft blobs with clear cut edges, 6=fluffy pieces with ragged edges, a mushy stool, 7=watery, no solid pieces. Data is reported for number of events in participants with each category of BSFR scale across Day 1 to 7 post morning dose.

    Time frame: Day 1 to 7 of each treatment period

  11. Number of Participants in Each Category of BSFR Across Day 1 to 7

    The BSFR Scale assessed stool quality using a 7-point scale, where 1=separate hard lumps like nuts (difficult to pass) and 7 = watery, no solid pieces (entirely liquid). Bristol Stool Form Scale Rating: 1=separate hard lumps, like nuts, 2=sausage shaped but lumpy, 3=like a sausage or snake but with cracks on its surface, 4=like a sausage or snake, smooth and soft, 5=soft blobs with clear cut edges, 6=fluffy pieces with ragged edges, a mushy stool, 7=watery, no solid pieces. Data is reported for number of events in participants with each category of BSFR scale across Day 1 to 7 post morning dose.

    Time frame: Day 1 to 7 of each treatment period

  12. Mean Change From Baseline in Overall Gastrointestinal Symptom Rating Scale (GSRS) Scores

    The impact of gastrointestinal (GI) symptoms on health-related quality of life was assessed using the GSRS. The GSRS is a 15-item related to abdominal pain, reflux, indigestion, diarrhea and constipation syndromes, self-administered questionnaire that assesses the impact of gastrointestinal symptoms during the past week on a scale from 1 (no discomfort at all) to 7 (very severe discomfort). Overall GSRS is the mean of questions 1-15 and range from 1 to 7, with lower scores indicating a better quality of life with respect to gastrointestinal symptoms. Baseline was defined as the assessment done on Day -1. Change from baseline was calculated by subtracting the baseline (Day -1) values from the post-baseline value (Day 8).

    Time frame: Baseline (Day -1) and Day 8 of each treatment period

Secondary outcomes

  1. Maximum and Weighted Mean Change From Baseline in Plasma Glucose Concentrations Over a 24 Hour (h) Period on Day 7

    Baseline was defined as the time matched assessment done on Day -1. Change from baseline was calculated by subtracting the baseline (Day -1) time matched values from the post-baseline value (Day 8). Data is reported for fasting glucose level and for weighted mean and maximum values for fasting, 0-4 h, 4-10 h, 10-14 h and 0-24 h. Area under the curve (AUC) with respect to these time interval was calculated using the linear trapezoidal rule by the sum of the areas between each chronological pair of assessments (using observed times). The weighted mean was then determined by dividing the AUC by the observed length of the collection interval (time of last assessment - time of first assessment in h). Analysis was done using analysis of covariance (ANCOVA) model where, change from baseline was summation of baseline, period, sequence and treatment. Participants were fitted as a random effect.

    Time frame: Baseline (Day -1) and Day 7 of each treatment period

  2. AUC From Time 0 to 10 h (AUC 0-10 h) of Metformin in Presence of GSK2330672 or Placebo on Day 7

    AUC(0-10) for metformin when co-dosed with GSK2330672 or placebo is defined as the the area under the plasma concentration-time curve from time 0 to 10 h. It was determined using the linear trapezoidal rule for increasing concentrations and the logarithmic trapezoidal rule for decreasing concentrations. Blood samples were collected at 0 h (pre-dose within 15 min of dose and began eating breakfast immediately after taking study drug and finished eating in 15 min), 0.25 h, 0.50 h, 1 h, 2 h, 3 h, 4 h (pre-lunch), 5 h, 5.5 h, 6 h, 8 h and 10 h (pre-dinner) on Day 7. Analysis was done using a mixed effects model with fixed effect terms for treatment, period, and sequence. Participant within sequence was fitted as a random effect in the model.

    Time frame: Pre-dose (0 h), 0.25 h, 0.50 h, 1 h, 2 h, 3 h, 4 h (pre-lunch), 5 h, 5.5 h, 6 h, 8 h and 10 h (pre-dinner) on Day 7 of each treatment period

  3. Maximum Plasma Concentration of Metformin (Cmax) in Presence of GSK2330672 or Placebo on Day 7

    Cmax is defined as the first occurrence of the maximum observed plasma concentration determined directly from the raw concentration-time data Blood samples were collected at 0 h (pre-dose within 15 min of dose and began eating breakfast immediately after taking study drug and finished eating in 15 min), 0.25 h, 0.50 h, 1 h, 2 h, 3 h, 4 h (pre-lunch), 5 h, 5.5 h, 6 h, 8 h and 10 h (pre-dinner) on Day 7. Analysis was done using a mixed effects model with fixed effect terms for treatment, period, and sequence. Participant within sequence was fitted as a random effect in the model.

    Time frame: Pre-dose (0 h), 0.25 h, 0.50 h, 1 h, 2 h, 3 h, 4 h (pre-lunch), 5 h, 5.5 h, 6 h, 8 h and 10 h (pre-dinner) on Day 7 of each treatment period

  4. Median Time to Observed Peak Plasma Concentration (Tmax) When Co-dosed With GSK2330672 or Placebo on Day 7

    Tmax is defined as the time at which Cmax is observed, determined directly from the raw concentration-time data. Blood samples were collected at 0 h (pre-dose within 15 min of dose and began eating breakfast immediately after taking study drug and finished eating in 15 min), 0.25 h, 0.50 h, 1 h, 2 h, 3 h, 4 h (pre-lunch), 5 h, 5.5 h, 6 h, 8 h and 10 h (pre-dinner) on Day 7.

    Time frame: Pre-dose (0 h), 0.25 h, 0.50 h, 1 h, 2 h, 3 h, 4 h (pre-lunch), 5 h, 5.5 h, 6 h, 8 h and 10 h (pre-dinner) on Day 7 of each treatment period

07

Results

Posted Aug 16, 2017

Participant flow

The study was planned on 16 participants with Type 2 diabetes mellitus (T2DM), aged 30 to 64 years, at a single center of United States from 22 August 2013 to 21 November 2013.

Period 1:Intervention Period 1 (7 Days)
Participant flow — Period 1:Intervention Period 1 (7 Days)
MilestoneMetformin and GSK2330672, Then Placebo and MetforminPlacebo and Metformin, Then Metformin and GSK2330672
Started78
Completed67
Not completed11
Withdrew: Adverse event10
Withdrew: Withdrawal by subject01
Period 2:Washout Period (13-15 Days)
Participant flow — Period 2:Washout Period (13-15 Days)
MilestoneMetformin and GSK2330672, Then Placebo and MetforminPlacebo and Metformin, Then Metformin and GSK2330672
Started67
Completed67
Not completed00
Period 3:Intervention Period 2 (7 Days)
Participant flow — Period 3:Intervention Period 2 (7 Days)
MilestoneMetformin and GSK2330672, Then Placebo and MetforminPlacebo and Metformin, Then Metformin and GSK2330672
Started67
Completed66
Not completed01
Withdrew: Adverse event01
Period 4:Follow-up-Metformin (7-10 Days)
Participant flow — Period 4:Follow-up-Metformin (7-10 Days)
MilestoneMetformin and GSK2330672, Then Placebo and MetforminPlacebo and Metformin, Then Metformin and GSK2330672
Started66
Completed00
Not completed66

Outcome measures

PrimaryNumber of Participants With at Least One Adverse Event (AE), Serious Adverse Event (SAE) or Death

An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in this definition, associated with liver injury and impaired liver function defined as alanine aminotransferase (ALT) \>=3 x upper limit of normal (ULN), and total bilirubin \>=2 x ULN or international normalized ratio \>1.5.

Time frame:
Up to Follow-up (up to 53 days)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Adverse Event (AE), Serious Adverse Event (SAE) or Death
ParticipantsTreatment A-GSK2330672 + MetforminTreatment B-Placebo + Metformin
Any AE129
Any SAE10
Any Death00
PrimaryNumber of Participants With the Indicated Clinical Chemistry Values of Potential Clinical Importance (PCI) at Any Time Post Baseline

The assessments were done at Day -1, Day 3, Day 8 and Follow-up under fasting condition. The following laboratory parameters of clinical chemistry were analyzed: blood urea nitrogen (BUN), creatinine, fasting triglycerides (TGs), total cholesterol, low-density lipoprotein cholesterol (LDLc), high-density lipoprotein cholesterol (HDLc), sodium, potassium, chloride, total bicarbonate, calcium, aspartate aminotransferase (AST), ALT, gamma glutamyltransferase (GGT), alkaline phosphatase, total and direct bilirubin, uric acid, albumin and total protein. Baseline was the assessment done on Day -1 (pre dose). Only those parameters for which at least one value of PCI was reported are summarized. Data is reported for participants with high glucose PCI, where the PCI value for T2DM participants was ( low \< 3.8857 millimole per liter (mmol/L); high \> 15 mmol/L; normal range was 3.61 - 5.5 mmol/L).

Time frame:
Up to Follow-up (up to 53 days)
Reported as:
Count of participants · Participants
Number of Participants With the Indicated Clinical Chemistry Values of Potential Clinical Importance (PCI) at Any Time Post Baseline
ParticipantsTreatment A-GSK2330672 + MetforminTreatment B-Placebo + MetforminFollow-up-Metformin
Number of Participants With the Indicated Clinical Chemistry Values of Potential Clinical Importance (PCI) at Any Time Post Baseline002
PrimaryNumber of Participants With the Indicated Haematology Values of PCI at Any Time Post Baseline

The assessments were done at Day -1, Day 3, Day 8 and Follow-up under fasting condition. The following laboratory parameters of clinical haematology were analyzed: platelet count, red blood cells (RBC) count, absolute white blood cells (WBC) count, reticulocyte count, hemoglobin, hematocrit, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline was the assessment done on Day -1 (pre dose). Only those parameters for which at least one value of PCI was reported are summarized. Data is reported for participants with high WBC counts PCI, where the PCI value for T2DM participants was (relative low : 0.5 multiplier of lower limit of normal \[LLN\]; relative high : 1.82 multiplier of upper limit of normal \[LLN\]; where normal range was 3.8 - 10.8 giga cells per liter (GI/L).

Time frame:
Up to Follow-up (up to 53 days)
Reported as:
Count of participants · Participants
Number of Participants With the Indicated Haematology Values of PCI at Any Time Post Baseline
ParticipantsTreatment A-GSK2330672 + MetforminTreatment B-Placebo + MetforminFollow-up-Metformin
Number of Participants With the Indicated Haematology Values of PCI at Any Time Post Baseline100
PrimaryNumber of Participants With Abnormal Values of Urine Microscopic Analysis of Bacteria, Hyaline Casts (Semi-quantitive), RBC, Squamous Epithelial Cells and WBC at Any Time Post Baseline

The assessments were done at Day -1, Day 3, Day 8 and Follow-up under fasting condition for microscopic analysis of bacteria, hyaline casts (semi-quantitive), RBC, squamous epithelial cells and WBC. Baseline was the assessment done on Day -1 (pre dose). The participants were categorized as 0-5, 6-10, 10-20, moderate, few and many. Only those parameters for which at least one value of these categories reported are summarized.

Time frame:
Up to Follow-up (up to 53 days)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Values of Urine Microscopic Analysis of Bacteria, Hyaline Casts (Semi-quantitive), RBC, Squamous Epithelial Cells and WBC at Any Time Post Baseline
ParticipantsTreatment A-GSK2330672 + MetforminTreatment B-Placebo + MetforminFollow-up-Metformin
Urine Microscopy, Bacteria, Day 3, Few01—
Urine Microscopy, Bacteria, Day 3, Many01—
Urine Microscopy, Bacteria, Day 8, Few11—
Urine Microscopy, Bacteria, Follow-up, Many——1
Urine Microscopy, SEC's, Day 3, 0-501—
Urine Microscopy, SEC's, Day 8, 0-501—
Urine Microscopy, SEC's, Follow-up, 0-5——1
Urine Microscopy, SEC's, Follow-up, 6-10——1
Urine Microscopy, WBC's, Day 3, 10-2001—
Urine Microscopy, WBC's, Follow-up, 0-5——1
Urine Microscopy, WBC's, Follow-up, 6-10——1
PrimaryNumber of Participants With Abnormal Values of Urine Dipstic Analysis of Occult Blood, Glucose, Ketones and Proteins at Any Visit Post Baseline

The assessments were done at Day -1, Day 3, Day 8 and Follow-up under fasting condition for urine dipstic analysis of occult blood, glucose, ketones and proteins. Baseline was the assessment done on Day -1 (pre dose). The participants were categorized with results of 1+, 2+, 3+ and trace. Only those parameters for which at least one value of these categories reported are summarized.

Time frame:
Up to Follow-up (up to 53 days)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Values of Urine Dipstic Analysis of Occult Blood, Glucose, Ketones and Proteins at Any Visit Post Baseline
ParticipantsTreatment A-GSK2330672 + MetforminTreatment B-Placebo + MetforminFollow-up-Metformin
Urine Glucose, Day 3, 1+13—
Urine Glucose, Day 3, 2+10—
Urine Glucose, Day 3, Trace11—
Urine Glucose, Day 8, 2+13—
Urine Glucose, Day 8, Trace25—
Urine Glucose, Follow-up, 3+——3
Urine Glucose, Follow-up, Trace——3
Urine Ketones, Day 3, Trace10—
Urine Ketones, Follow-up, Trace——2
Urine Protein, Follow-up, Trace——1
PrimaryMean Specific Gravity of Urine at Any Visit Post Baseline

Urine specific gravity is a laboratory test that shows the concentration of all chemical particles in the urine. The assessments were done at Day -1, Day 3, Day 8 and Follow-up under fasting condition. Baseline was the assessment done on Day -1 (pre dose).

Time frame:
Up to Follow-up (up to 53 days)
Reported as:
Mean · Ratio
Mean Specific Gravity of Urine at Any Visit Post Baseline
RatioTreatment A-GSK2330672 + MetforminTreatment B-Placebo + MetforminFollow-up-Metformin
Day 31.0121 ± 0.003521.0110 ± 0.00335—
Day 81.0125 ± 0.006541.0109 ± 0.00386—
Follow-up——1.0203 ± 0.00832
PrimaryNumber of Participants With Abnormal Results for Fecal Occult Blood Test

The assessment of fecal occult blood was done on Day 8. Stool sample was obtained any time after dosing on Day 7.

Time frame:
Day 8 of both treatment periods
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Results for Fecal Occult Blood Test
ParticipantsTreatment A-GSK2330672 + MetforminTreatment B-Placebo + Metformin
Number of Participants With Abnormal Results for Fecal Occult Blood Test00
PrimaryNumber of Participants With Vital Sign Values of PCI at Any Time Post Baseline

Vital signs assessment included heart rate (HR), systolic blood pressure (SBP) and diastolic blood pressure (DBP). Assessments were completed at pre morning dose on Day 1 (Baseline), Day 3, Day 8 (before discharge) and Follow-up. Criteria for vital sign values meeting PCI for Type 2 diabetes mellitus (T2DM) included: SBP \<85 and \>160 millimeters of mercury (mmHg), DBP \<45 and \>100 mmHg and HR \<40 and \>110 beats per minute (bpm). Only those parameters for which at least one value of PCI was reported are summarized.

Time frame:
Up to Follow-up (up to 53 days)
Reported as:
Count of participants · Participants
Number of Participants With Vital Sign Values of PCI at Any Time Post Baseline
ParticipantsTreatment A-GSK2330672 + MetforminTreatment B-Placebo + MetforminFollow-up-Metformin
SBP010
HR100
PrimaryNumber of Participants With Abnormal (Clinically Significant or Not Clinically Significant) Findings in 12-lead Electrocardiogram (ECG) at Any Time Post Baseline

12-lead ECG assessments were obtained pre-dose at Day 1, Day 3, Day 8 (before discharge) and Follow-up. The assessments were done using an ECG machine that automatically calculated the heart rate and measures PQ, QRS, QT, and QTc(B) intervals. Abnormal ECG findings (clinically significant or not clinically significant) were categorized. The abnormal PCI range for T2DM participants include QTc interval of \>450 to \<=480 milliseconds (msec) and increase from Baseline QTc interval of \> 30 to \<=60 msec, PR interval \<110 and \>220 msec and QRS interval \<75 and \>110 msec. ECG abnormalities were categorized as clinically significant or not clinically significant based on PCI criteria and judgment of the investigator. Baseline was defined as the mean of three replicate assessments at pre-dose on Day 1.

Time frame:
Up to Follow-up (up to 53 days)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal (Clinically Significant or Not Clinically Significant) Findings in 12-lead Electrocardiogram (ECG) at Any Time Post Baseline
ParticipantsTreatment A-GSK2330672 + MetforminTreatment B-Placebo + MetforminFollow-up-Metformin
Not-clinically Significant, Day 332—
Clinically Significant, Day 300—
Not-clinically Significant, Day 824—
Clinically Significant, Day 800—
Not-clinically Significant, Follow-up——3
Clinically Significant, Follow-up——0
PrimaryNumber of Events of Stool or Bowel Movements of Participants Using Bristol Stool Form Rating (BSFR) Scale Across Day 1 to 7

The BSFR Scale assessed stool quality using a 7-point scale, where 1=separate hard lumps like nuts (difficult to pass) and 7=watery, no solid pieces (entirely liquid). Bristol Stool Form Scale Rating: 1=separate hard lumps, like nuts, 2=sausage shaped but lumpy, 3=like a sausage or snake but with cracks on its surface, 4=like a sausage or snake, smooth and soft, 5=soft blobs with clear cut edges, 6=fluffy pieces with ragged edges, a mushy stool, 7=watery, no solid pieces. Data is reported for number of events in participants with each category of BSFR scale across Day 1 to 7 post morning dose.

Time frame:
Day 1 to 7 of each treatment period
Reported as:
Number · Number of events
Number of Events of Stool or Bowel Movements of Participants Using Bristol Stool Form Rating (BSFR) Scale Across Day 1 to 7
Number of eventsTreatment A-GSK2330672 + MetforminTreatment B-Placebo + Metformin
Participants with Rating 106
Participants with Rating 244
Participants with Rating 348
Participants with Rating 41120
Participants with Rating 51815
Participants with Rating 66017
Participants with Rating 711116
PrimaryNumber of Participants in Each Category of BSFR Across Day 1 to 7

The BSFR Scale assessed stool quality using a 7-point scale, where 1=separate hard lumps like nuts (difficult to pass) and 7 = watery, no solid pieces (entirely liquid). Bristol Stool Form Scale Rating: 1=separate hard lumps, like nuts, 2=sausage shaped but lumpy, 3=like a sausage or snake but with cracks on its surface, 4=like a sausage or snake, smooth and soft, 5=soft blobs with clear cut edges, 6=fluffy pieces with ragged edges, a mushy stool, 7=watery, no solid pieces. Data is reported for number of events in participants with each category of BSFR scale across Day 1 to 7 post morning dose.

Time frame:
Day 1 to 7 of each treatment period
Reported as:
Count of participants · Participants
Number of Participants in Each Category of BSFR Across Day 1 to 7
ParticipantsTreatment A-GSK2330672 + MetforminTreatment B-Placebo + Metformin
Rating 104
Rating 233
Rating 346
Rating 4510
Rating 586
Rating 6128
Rating 7146
PrimaryMean Change From Baseline in Overall Gastrointestinal Symptom Rating Scale (GSRS) Scores

The impact of gastrointestinal (GI) symptoms on health-related quality of life was assessed using the GSRS. The GSRS is a 15-item related to abdominal pain, reflux, indigestion, diarrhea and constipation syndromes, self-administered questionnaire that assesses the impact of gastrointestinal symptoms during the past week on a scale from 1 (no discomfort at all) to 7 (very severe discomfort). Overall GSRS is the mean of questions 1-15 and range from 1 to 7, with lower scores indicating a better quality of life with respect to gastrointestinal symptoms. Baseline was defined as the assessment done on Day -1. Change from baseline was calculated by subtracting the baseline (Day -1) values from the post-baseline value (Day 8).

Time frame:
Baseline (Day -1) and Day 8 of each treatment period
Reported as:
Mean · Score on scale
Mean Change From Baseline in Overall Gastrointestinal Symptom Rating Scale (GSRS) Scores
Score on scaleTreatment A-GSK2330672 + MetforminTreatment B-Placebo + Metformin
Mean Change From Baseline in Overall Gastrointestinal Symptom Rating Scale (GSRS) Scores0.59 ± 0.8910.08 ± 0.468
SecondaryMaximum and Weighted Mean Change From Baseline in Plasma Glucose Concentrations Over a 24 Hour (h) Period on Day 7

Baseline was defined as the time matched assessment done on Day -1. Change from baseline was calculated by subtracting the baseline (Day -1) time matched values from the post-baseline value (Day 8). Data is reported for fasting glucose level and for weighted mean and maximum values for fasting, 0-4 h, 4-10 h, 10-14 h and 0-24 h. Area under the curve (AUC) with respect to these time interval was calculated using the linear trapezoidal rule by the sum of the areas between each chronological pair of assessments (using observed times). The weighted mean was then determined by dividing the AUC by the observed length of the collection interval (time of last assessment - time of first assessment in h). Analysis was done using analysis of covariance (ANCOVA) model where, change from baseline was summation of baseline, period, sequence and treatment. Participants were fitted as a random effect.

Time frame:
Baseline (Day -1) and Day 7 of each treatment period
Reported as:
Mean · mg/deciliter
Maximum and Weighted Mean Change From Baseline in Plasma Glucose Concentrations Over a 24 Hour (h) Period on Day 7
mg/deciliterTreatment A-GSK2330672 + MetforminTreatment B-Placebo + Metformin
Fasting Value-12.325 ± 36.12777.479 ± 44.6181
Maximum (0-4 h)6.250 ± 45.227022.857 ± 49.1307
Maximum (4-10 h)-6.583 ± 45.440229.714 ± 42.1251
Maximum (10-14 h)2.500 ± 51.3481940.307 ± 56.18196
Maximum (0-24 h)4.583 ± 45.902023.071 ± 39.6959
AUC (0-4 h) Weighted Mean6.0737 ± 43.3733622.0247 ± 46.54980
AUC (4-10 h) Weighted Mean-4.6051 ± 43.3108324.7262 ± 39.21502
AUC (10-14 h) Weighted Mean4.4221 ± 55.0020138.2479 ± 51.91011
AUC (0-24 h) Weighted Mean-2.0829 ± 44.7664526.0704 ± 40.74711
Statistical analysis
  • Treatment A-GSK2330672 + Metformin vs Treatment B-Placebo + Metformin · Mean difference (net): -28.13 · 95% CI -50.40 to -5.86The point estimate was calculated as least square mean difference (net values) of Treatment A-GSK2330672 + Metformin and Treatment B-Placebo + Metformin for Fasting Value.
  • Treatment A-GSK2330672 + Metformin vs Treatment B-Placebo + Metformin · Mean difference (net): -29.16 · 95% CI -51.68 to -6.64The point estimate was calculated as least square mean difference (net values) of Treatment A-GSK2330672 + Metformin and Treatment B-Placebo + Metformin for Maximum (0-4 h) Value.
  • Treatment A-GSK2330672 + Metformin vs Treatment B-Placebo + Metformin · Mean difference (net): -36.58 · 95% CI -62.25 to -10.90The point estimate was calculated as least square mean difference (net values) of Treatment A-GSK2330672 + Metformin and Treatment B-Placebo + Metformin for Maximum (4-10 h) Value.
  • Treatment A-GSK2330672 + Metformin vs Treatment B-Placebo + Metformin · Mean difference (net): -45.41 · 95% CI -72.80 to -18.03The point estimate was calculated as least square mean difference (net values) of Treatment A-GSK2330672 + Metformin and Treatment B-Placebo + Metformin for Maximum (10-14 h) Value.
  • Treatment A-GSK2330672 + Metformin vs Treatment B-Placebo + Metformin · Mean difference (net): -29.35 · 95% CI -50.84 to -7.86The point estimate was calculated as least square mean difference (net values) of Treatment A-GSK2330672 + Metformin and Treatment B-Placebo + Metformin for Maximum (0-24 h) Value.
  • Treatment A-GSK2330672 + Metformin vs Treatment B-Placebo + Metformin · Mean difference (net): -26.14 · 95% CI -45.80 to -6.49The point estimate was calculated as least square mean difference (net values) of Treatment A-GSK2330672 + Metformin and Treatment B-Placebo + Metformin for AUC (0-4 h) Weighted Mean.
  • Treatment A-GSK2330672 + Metformin vs Treatment B-Placebo + Metformin · Mean difference (net): -32.00 · 95% CI -55.41 to -8.58The point estimate was calculated as least square mean difference (net values) of Treatment A-GSK2330672 + Metformin and Treatment B-Placebo + Metformin for AUC (4-10 h) Weighted Mean.
  • Treatment A-GSK2330672 + Metformin vs Treatment B-Placebo + Metformin · Mean difference (net): -40.96 · 95% CI -66.64 to -15.29The point estimate was calculated as least square mean difference (net values) of Treatment A-GSK2330672 + Metformin and Treatment B-Placebo + Metformin for AUC (10-14 h) Weighted Mean.
  • Treatment A-GSK2330672 + Metformin vs Treatment B-Placebo + Metformin · Mean difference (net): -34.76 · 95% CI -54.67 to -14.85The point estimate was calculated as least square mean difference (net values) of Treatment A-GSK2330672 + Metformin and Treatment B-Placebo + Metformin for AUC (0-24 h) Weighted Mean.
SecondaryAUC From Time 0 to 10 h (AUC 0-10 h) of Metformin in Presence of GSK2330672 or Placebo on Day 7

AUC(0-10) for metformin when co-dosed with GSK2330672 or placebo is defined as the the area under the plasma concentration-time curve from time 0 to 10 h. It was determined using the linear trapezoidal rule for increasing concentrations and the logarithmic trapezoidal rule for decreasing concentrations. Blood samples were collected at 0 h (pre-dose within 15 min of dose and began eating breakfast immediately after taking study drug and finished eating in 15 min), 0.25 h, 0.50 h, 1 h, 2 h, 3 h, 4 h (pre-lunch), 5 h, 5.5 h, 6 h, 8 h and 10 h (pre-dinner) on Day 7. Analysis was done using a mixed effects model with fixed effect terms for treatment, period, and sequence. Participant within sequence was fitted as a random effect in the model.

Time frame:
Pre-dose (0 h), 0.25 h, 0.50 h, 1 h, 2 h, 3 h, 4 h (pre-lunch), 5 h, 5.5 h, 6 h, 8 h and 10 h (pre-dinner) on Day 7 of each treatment period
Reported as:
Geometric mean · Nanogram (ng)*h/mL
AUC From Time 0 to 10 h (AUC 0-10 h) of Metformin in Presence of GSK2330672 or Placebo on Day 7
Nanogram (ng)*h/mLTreatment A-GSK2330672 + MetforminTreatment B-Placebo + Metformin
AUC From Time 0 to 10 h (AUC 0-10 h) of Metformin in Presence of GSK2330672 or Placebo on Day 79189.2649 ± 34.0809232.5372 ± 24.404
Statistical analysis
  • Treatment A-GSK2330672 + Metformin vs Treatment B-Placebo + Metformin · Ratio: 1.013 · 90% CI 0.912 to 1.125The point estimate was calculated as geometric least square mean ratio of Treatment A-GSK2330672 + Metformin and Treatment B-Placebo + Metformin for AUC (0-10 h).
SecondaryMaximum Plasma Concentration of Metformin (Cmax) in Presence of GSK2330672 or Placebo on Day 7

Cmax is defined as the first occurrence of the maximum observed plasma concentration determined directly from the raw concentration-time data Blood samples were collected at 0 h (pre-dose within 15 min of dose and began eating breakfast immediately after taking study drug and finished eating in 15 min), 0.25 h, 0.50 h, 1 h, 2 h, 3 h, 4 h (pre-lunch), 5 h, 5.5 h, 6 h, 8 h and 10 h (pre-dinner) on Day 7. Analysis was done using a mixed effects model with fixed effect terms for treatment, period, and sequence. Participant within sequence was fitted as a random effect in the model.

Time frame:
Pre-dose (0 h), 0.25 h, 0.50 h, 1 h, 2 h, 3 h, 4 h (pre-lunch), 5 h, 5.5 h, 6 h, 8 h and 10 h (pre-dinner) on Day 7 of each treatment period
Reported as:
Geometric mean · ng/mL
Maximum Plasma Concentration of Metformin (Cmax) in Presence of GSK2330672 or Placebo on Day 7
ng/mLTreatment A-GSK2330672 + MetforminTreatment B-Placebo + Metformin
Maximum Plasma Concentration of Metformin (Cmax) in Presence of GSK2330672 or Placebo on Day 71707.1 ± 281638.3 ± 25
Statistical analysis
  • Treatment A-GSK2330672 + Metformin vs Treatment B-Placebo + Metformin · Ratio: 1.036 · 90% CI 0.937 to 1.145The point estimate was calculated as geometric least square mean ratio of Treatment A-GSK2330672 + Metformin and Treatment B-Placebo + Metformin for Cmax.
SecondaryMedian Time to Observed Peak Plasma Concentration (Tmax) When Co-dosed With GSK2330672 or Placebo on Day 7

Tmax is defined as the time at which Cmax is observed, determined directly from the raw concentration-time data. Blood samples were collected at 0 h (pre-dose within 15 min of dose and began eating breakfast immediately after taking study drug and finished eating in 15 min), 0.25 h, 0.50 h, 1 h, 2 h, 3 h, 4 h (pre-lunch), 5 h, 5.5 h, 6 h, 8 h and 10 h (pre-dinner) on Day 7.

Time frame:
Pre-dose (0 h), 0.25 h, 0.50 h, 1 h, 2 h, 3 h, 4 h (pre-lunch), 5 h, 5.5 h, 6 h, 8 h and 10 h (pre-dinner) on Day 7 of each treatment period
Reported as:
Median · h
Median Time to Observed Peak Plasma Concentration (Tmax) When Co-dosed With GSK2330672 or Placebo on Day 7
hTreatment A-GSK2330672 + MetforminTreatment B-Placebo + Metformin
Median Time to Observed Peak Plasma Concentration (Tmax) When Co-dosed With GSK2330672 or Placebo on Day 71.4583 (0.500 to 2.000)1.0000 (1.000 to 2.000)

Adverse events

Collected over AE's and SAE's were collected from the start of study treatment of metformin in the run-in period and until Follow-up (up to 53 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A-GSK2330672 + Metformin0/14 (0%)1/14 (7.1%)12/14 (85.7%)
Treatment B-Placebo + Metformin0/14 (0%)0/14 (0%)9/14 (64.3%)
Most frequent serious events
Most frequent serious events
EventTreatment A-GSK2330672 + MetforminTreatment B-Placebo + Metformin
Cholecystitis acuteHepatobiliary disorders1/140/14
Most frequent other events
Most frequent other events
EventTreatment A-GSK2330672 + MetforminTreatment B-Placebo + Metformin
DiarrhoeaGastrointestinal disorders11/147/14
HeadacheNervous system disorders1/143/14
Abdominal painGastrointestinal disorders2/140/14
Abdominal pain upperGastrointestinal disorders2/140/14
NauseaGastrointestinal disorders1/140/14
VomitingGastrointestinal disorders1/140/14
Back painMusculoskeletal and connective tissue disorders1/140/14
Neck painMusculoskeletal and connective tissue disorders0/141/14
PyrexiaGeneral disorders1/140/14
Blood glucose increasedInvestigations0/141/14

Baseline characteristics

Age, Continuous
Age, Continuous(Years)All Study Participants
Mean54.9 ± 7.06
Sex: Female, Male
Sex: Female, Male(Participants)All Study Participants
Female9
Male6
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Study Participants
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American2
White12
More than one race1
Unknown or Not Reported0
08

Study locations

1 site
  • GSK Investigational Site
    Miami, Florida 33169, United States
09

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2013, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2017, 3 years 9 months after primary completion. A results delay was requested in Apr 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2013
First posted
Aug 28, 2013
Start
Aug 1, 2013
Primary completionActual
Nov 1, 2013
CompletionActual
Nov 21, 2013
Results delay requested
Apr 24, 2014
Results first posted
Aug 16, 2017
Last update
Aug 16, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 16, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01929863
Lead sponsor
GlaxoSmithKline
Collaborators
Elite Research Institute
Responsible party
Sponsor
First posted
Aug 28, 2013
Start date
Aug 1, 2013
Primary completion
Nov 1, 2013
Completion
Nov 21, 2013
Results posted
Aug 16, 2017
Last update
Aug 16, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linerixibat

Start the discussion